KR102713354B1 - 선택적 p2x3 조정제 - Google Patents

선택적 p2x3 조정제 Download PDF

Info

Publication number
KR102713354B1
KR102713354B1 KR1020207010982A KR20207010982A KR102713354B1 KR 102713354 B1 KR102713354 B1 KR 102713354B1 KR 1020207010982 A KR1020207010982 A KR 1020207010982A KR 20207010982 A KR20207010982 A KR 20207010982A KR 102713354 B1 KR102713354 B1 KR 102713354B1
Authority
KR
South Korea
Prior art keywords
selective
antagonist
patient
receptor antagonism
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207010982A
Other languages
English (en)
Korean (ko)
Other versions
KR20200092938A (ko
Inventor
데니스 게르소
안토니오스 마트조우라니스
로베르토 벨리니
케말 페이자
나탈리 차우렛
수잔 이. 브라운
Original Assignee
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 3) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 3) 리미티드 filed Critical 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 3) 리미티드
Publication of KR20200092938A publication Critical patent/KR20200092938A/ko
Application granted granted Critical
Publication of KR102713354B1 publication Critical patent/KR102713354B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
KR1020207010982A 2017-09-18 2018-09-14 선택적 p2x3 조정제 Active KR102713354B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762560077P 2017-09-18 2017-09-18
US62/560,077 2017-09-18
US15/936,316 US10111883B1 (en) 2017-09-18 2018-03-26 Selective P2X3 modulators
US15/936,316 2018-03-26
PCT/IB2018/001513 WO2019064079A2 (en) 2017-09-18 2018-09-14 SELECTIVE MODULATORS OF P2X3

Publications (2)

Publication Number Publication Date
KR20200092938A KR20200092938A (ko) 2020-08-04
KR102713354B1 true KR102713354B1 (ko) 2024-10-02

Family

ID=63894683

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207010982A Active KR102713354B1 (ko) 2017-09-18 2018-09-14 선택적 p2x3 조정제

Country Status (12)

Country Link
US (6) US10111883B1 (enExample)
EP (2) EP4331669A3 (enExample)
JP (1) JP7242681B2 (enExample)
KR (1) KR102713354B1 (enExample)
CN (1) CN111601601A (enExample)
AU (1) AU2018342751B2 (enExample)
CA (1) CA3076150C (enExample)
ES (1) ES2969868T3 (enExample)
IL (2) IL273348B2 (enExample)
MX (1) MX2020002968A (enExample)
SG (1) SG11202002460QA (enExample)
WO (1) WO2019064079A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019353424B2 (en) * 2018-10-05 2022-12-08 Shionogi & Co., Ltd. Medicine for treating chronic cough
AU2019358327B2 (en) * 2018-10-10 2025-04-24 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment of pruritus with P2X3 antagonists
FI3880678T3 (fi) 2018-11-13 2025-08-01 Glaxosmithkline Intellectual Property N0 3 Ltd P2x3-muuntaja metyyli-(s)-2-((2-(2,6-difluori-4-(metyylikarbamoyyli)fenyyli)-7-metyyli-imidatso[1,2-a]pyridin-3-yyli)metyyli)morfoliini-4-karboksylaatin kidemuotoja
JP2022515879A (ja) * 2018-12-29 2022-02-22 武漢朗来科技発展有限公司 複素環式化合物、中間体、その製造方法及び応用 本願は、出願日が２０１８年１２月２９日の中国特許出願ｃｎ ２０１８１１６４２３１９、出願日が２０１９年０５月２４日の中国特許出願ｃｎ２０１９１０４４０２１４．３及び出願日が２０１９年１０月２４日の中国特許出願ｃｎ２０１９１１０１６１５８．７に基づいて優先権を主張する。また、上記中国特許出願の全文は本願に援用される。
WO2020174283A1 (en) * 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
CN112409331B (zh) * 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
MX2022009762A (es) * 2020-02-14 2022-09-09 Bellus Health Cough Inc Moduladores del purinorreceptor 3 p2x (p2x3).
EP4142784A4 (en) 2020-04-27 2024-12-18 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CORONAVIRUS
WO2021244634A1 (zh) * 2020-06-05 2021-12-09 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
EP4169921A4 (en) * 2020-06-29 2024-06-19 Wuhan LL Science and Technology Development Co., Ltd. Crystalline form of heterocyclic compound, preparation method therefor and application thereof
US20240408131A1 (en) * 2020-07-06 2024-12-12 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions
US20230218661A1 (en) * 2022-01-10 2023-07-13 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx
CN113912601B (zh) * 2020-07-10 2023-06-06 上海拓界生物医药科技有限公司 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途
CA3187092A1 (en) * 2020-08-13 2022-02-17 Wenming Li Benzimidazole derivatives, preparation method therefor and medical use thereof
CN116635389A (zh) * 2021-01-29 2023-08-22 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
CN115463133B (zh) * 2021-06-10 2024-03-01 武汉朗来科技发展有限公司 一种药物组合物、制剂及其制备方法和应用
WO2023020156A1 (zh) * 2021-08-20 2023-02-23 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
CN120917022A (zh) 2023-03-23 2025-11-07 葛兰素史密斯克莱知识产权(第3号)有限公司 氘代p2x3调节剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102120513B1 (ko) 2013-01-31 2020-06-08 네오메드 인스티튜트 이미다조피리딘 화합물 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2501697B1 (en) * 2009-11-18 2013-10-23 Neomed Institute Benzoimidazole compounds and uses thereof
KR101790370B1 (ko) * 2010-03-19 2017-10-25 유니버시티 오브 마이애미 췌장 베타 세포에서 인슐린 분비를 향상시키기 위한 ｐ２ｘ 퓨린성 수용체 효능제의 용도
US9284279B2 (en) * 2013-08-23 2016-03-15 Afferent Pharmaceuticals, Inc. Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough
RS63014B1 (sr) * 2014-12-09 2022-04-29 Bayer Ag 1,3-tiazol-2-il supstituisani benzamidi
LT3355889T (lt) 2015-09-29 2023-05-10 Afferent Pharmaceuticals Inc. Diaminopirimidino p2x3 ir p2x2/3 receptorių moduliatoriai, skirti panaudoti gydant kosulį
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
CN116854693A (zh) * 2016-09-30 2023-10-10 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102120513B1 (ko) 2013-01-31 2020-06-08 네오메드 인스티튜트 이미다조피리딘 화합물 및 이의 용도

Also Published As

Publication number Publication date
EP3684368A4 (en) 2021-05-26
CA3076150C (en) 2024-01-02
KR20200092938A (ko) 2020-08-04
US20200230148A1 (en) 2020-07-23
WO2019064079A2 (en) 2019-04-04
JP2020534355A (ja) 2020-11-26
EP4331669A2 (en) 2024-03-06
WO2019064079A3 (en) 2019-05-16
US20210069201A1 (en) 2021-03-11
US20210322432A1 (en) 2021-10-21
SG11202002460QA (en) 2020-04-29
US20220160724A1 (en) 2022-05-26
EP3684368B1 (en) 2024-01-03
JP7242681B2 (ja) 2023-03-20
AU2018342751B2 (en) 2023-06-15
AU2018342751A1 (en) 2020-04-23
IL303257A (en) 2023-07-01
US10111883B1 (en) 2018-10-30
US20230248736A1 (en) 2023-08-10
EP3684368B8 (en) 2024-02-14
MX2020002968A (es) 2020-08-17
EP4331669A3 (en) 2024-05-01
IL273348A (en) 2020-05-31
ES2969868T3 (es) 2024-05-23
CA3076150A1 (en) 2019-04-04
IL273348B1 (en) 2023-07-01
CN111601601A (zh) 2020-08-28
EP3684368A2 (en) 2020-07-29
IL273348B2 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
KR102713354B1 (ko) 선택적 p2x3 조정제
EP3328858B1 (en) Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
JP4898062B2 (ja) アザ二環式カルバメートおよびアルファ−７ニコチン性アセチルコリンレセプターアゴニストとしてのその使用
JP6163695B2 (ja) 新しいインダニルオキシフェニルシクロプロパンカルボン酸
JP6816107B2 (ja) インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用
JPH05501540A (ja) Ｐｃｐレセプター・リガンドおよびその用途
CN119039290A (zh) P2x3调节剂
EP3914589A1 (en) Methods of treating disease with magl inhibitors
JP7013446B2 (ja) Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法
JPWO2014092061A1 (ja) ヒダントイン誘導体
US20150232473A1 (en) Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
CN102112469B (zh) 神经元nAChR的安静减敏剂及其使用方法
HK40036201A (en) Selective p2x3 modulators
JP2008513380A (ja) ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途
WO2024194352A1 (en) Deuterated p2x3 modulators
JPH0832688B2 (ja) フェノキシ酢酸誘導体及びこれを含有する医薬製剤
HK1065537A1 (zh) 作为抗抑郁药的异恶唑啉衍生物
HK1065537B (en) Isoxazoline derivatives as anti-depressants
JPS6330442A (ja) 新規リグナン誘導体およびこれを有効成分とする抗潰瘍剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601